In non-small cell lung cancer (NSCLC) cells, knockdown of FOXC1 impaired self-renewal, downregulated CD133 and other ‘stemness’ markers, dampened in vivo tumorigenicity, and increased sensitization to chemotherapy [56]. Here, FOXC1 is linked to non-small cell lung carcinoma.